KRAS and pancreatic adenocarcinoma: It is noteworthy that both HLA-A02+B62+B44− and its ‘indicator’ KRAS G12D and TP53 co-mutations failed to exhibit prognostic significance in advanced or metastatic PAAD patients of our cohort or public cohort, which is likely owing to the widespread immunosuppression and ineffective immunoediting in late-stage PAAD than in early-stage PAAD5,30.